Literature DB >> 22752473

Introduction: personalized medicine in gastrointestinal cancer.

Taylor S Riall1.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22752473     DOI： 10.1007/s11605-012-1948-9

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN： 1091-255X            Impact factor:   3.452


× No keyword cloud information.
  15 in total

1.  Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations.

Authors:  Dimitrios H Roukos; Niki J Agnanti; Evangelos Paraskevaidis; Angelos M Kappas
Journal:  Ann Surg Oncol       Date:  2002-12       Impact factor: 5.344

2.  Role of surgery in the prophylaxis of hereditary cancer syndromes.

Authors:  Dimitrios H Roukos; Aggelos M Kappas; Epameinondas Tsianos
Journal:  Ann Surg Oncol       Date:  2002-08       Impact factor: 5.344

3.  Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance.

Authors:  Niki J Agnantis; Evangelos Paraskevaidis; Dimitrios Roukos
Journal:  Ann Surg Oncol       Date:  2004-11-15       Impact factor: 5.344

4.  Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations.

Authors:  Dimitrios H Roukos
Journal:  N Engl J Med       Date:  2007-10-11       Impact factor: 91.245

5.  Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.

Authors:  Gordon Hutchins; Katie Southward; Kelly Handley; Laura Magill; Claire Beaumont; Jens Stahlschmidt; Susan Richman; Philip Chambers; Matthew Seymour; David Kerr; Richard Gray; Philip Quirke
Journal:  J Clin Oncol       Date:  2011-03-07       Impact factor: 44.544

6.  DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.

Authors:  Christine A Iacobuzio-Donahue; Baojin Fu; Shinichi Yachida; Mingde Luo; Hisashi Abe; Clark M Henderson; Felip Vilardell; Zheng Wang; Jesse W Keller; Priya Banerjee; Joseph M Herman; John L Cameron; Charles J Yeo; Marc K Halushka; James R Eshleman; Marian Raben; Alison P Klein; Ralph H Hruban; Manuel Hidalgo; Daniel Laheru
Journal:  J Clin Oncol       Date:  2009-03-09       Impact factor: 44.544

7.  Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy.

Authors:  F Di Fiore; F Blanchard; F Charbonnier; F Le Pessot; A Lamy; M P Galais; L Bastit; A Killian; R Sesboüé; J J Tuech; A M Queuniet; B Paillot; J C Sabourin; F Michot; P Michel; T Frebourg
Journal:  Br J Cancer       Date:  2007-03-20       Impact factor: 7.640

Review 8.  Familial gastric cancer - aetiology and pathogenesis.

Authors:  Miriam Barber; Rebecca C Fitzgerald; Carlos Caldas
Journal:  Best Pract Res Clin Gastroenterol       Date:  2006       Impact factor: 3.043

Review 9.  Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma.

Authors:  H Schulz; J Bohlius; N Skoetz; S Trelle; T Kober; M Reiser; M Dreyling; M Herold; G Schwarzer; M Hallek; A Engert
Journal:  Cochrane Database Syst Rev       Date:  2007-10-17

Review 10.  Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials.

Authors:  Gustavo A Viani; Sergio L Afonso; Eduardo J Stefano; Ligia I De Fendi; Francisco V Soares
Journal:  BMC Cancer       Date:  2007-08-08       Impact factor: 4.430
View more
  1 in total

Review 1.  From conventional chemotherapy to targeted therapy: use of monoclonal antibodies (moAbs) in gastrointestinal (GI) tumors.

Authors:  Federica Zoratto; L Rossi; E Giordani; M Strudel; A Papa; S Tomao
Journal:  Tumour Biol       Date:  2014-07-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.